REC Ref:12/LO/0393EudraCT:2011-005606-30Clinical Trials Gov NCT01712945Full Title:Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab Campath-1H) treatment of multiple sclerosis.Short Title: CAM-THYFunding: Medical research Council and the Moulton FoundationEU Clinical Trials Register
What is the rationale of the “CAM-THY” trial?
We have shown that lymphocyte reconstitution after alemtuzumab is via expansion of peripheral lymphocytes. We are testing whether promotion of thymic reconstitution will prevent autoimmunity. We are using human recombinant keratincoyte growth factor, which is marketed as Palifermin as a treatment of stomatitis associated with chemotherapy. In animals, it effectively promote thymic lymphopoeisis.
•age 18-50•relapsing-remitting mutiple sclerosis, •within ten years of the first symptoms of multiple sclerosis, •EDSS 5.5 or less•at least 2 clinical episodes of MS in the previous 2 years, which may have occurred whilst on disease-modifying therapy.
Patient Information Sheet
Patient Information Sheet[Provided here for your reference only. NRES Hampstead has allowed us to publish a downloadable version of this patient infomation sheet on the patient pages of this website.]